<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="290">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891982</url>
  </required_header>
  <id_info>
    <org_study_id>114679</org_study_id>
    <secondary_id>W0265-306</secondary_id>
    <nct_id>NCT00891982</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash</brief_title>
  <official_title>A Phase 3, Multicenter, Assessor-Blinded Study Of The Tolerability Of a Topical Antibiotic and Retinoid Used In Conjunction With Benzoyl Peroxide Wash In Subjects With Mild-To-Moderate Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability of a combined regimen of a topical
      antibiotic and retinoid and a benzoyl peroxide wash.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Local Tolerability - Skin Dryness</measure>
    <time_frame>Screening/baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Dryness</measure>
    <time_frame>Week 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Dryness</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Dryness</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Scaling</measure>
    <time_frame>Screening/baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Scaling</measure>
    <time_frame>Week 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Scaling</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Skin Scaling</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Erythema (Redness)</measure>
    <time_frame>Screening/baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Erythema (Redness)</measure>
    <time_frame>Week 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Erythema (Redness)</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability - Erythema (Redness)</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Local tolerability and irritation potential based on investigator assessments of dryness, scaling, and erythema in the areas of study product application.  Grading will use the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Burning/Stinging</measure>
    <time_frame>Screening/baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Burning/Stinging</measure>
    <time_frame>Week 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Burning/Stinging</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Burning/Stinging</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Itching</measure>
    <time_frame>Screening/Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Itching</measure>
    <time_frame>Week 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Itching</measure>
    <time_frame>Week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Itching</measure>
    <time_frame>Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each symptom will be graded by the subject based upon the subject's impression during the previous week using the following scale:
0 - None
- Trace
- Mild
- Moderate
- Marked
- Severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CTGel plus BPO wash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTGel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Soap Free Cleanser in the morning and CTGel in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTGel/ BPO Wash</intervention_name>
    <description>Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days
Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.</description>
    <arm_group_label>CTGel plus BPO wash</arm_group_label>
    <other_name>Veltin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soap Free Cleanser and CTGel</intervention_name>
    <description>Soap Free Cleanser will be used once daily in the morning for 28 days
Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days.</description>
    <arm_group_label>CTGel</arm_group_label>
    <other_name>Veltin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with mild to moderate facial acne vulgaris, with no history of known or
             suspected hypersensitivity or previous allergic reaction to any of the ingredients of
             the study products (eg, topical antibiotics, retinoids or  benzoyl peroxide), capable
             of understanding and willing to provide signed and dated written voluntary informed
             consent and able to complete the study and to comply with study instructions.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test
             result at baseline and practice a reliable method of contraception throughout the
             study.

        Exclusion Criteria:

          -  Use of topical antibiotics on the face within the past 2 weeks or use of systemic
             antibiotics within the past 4 weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Associates Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Draelos ZD, Potts A, Ali√≥ Saenz AB; W0265-306 Study Group. Randomized tolerability analysis of clindamycin phosphate 1.2%-tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris. Cutis. 2010 Dec;86(6):310-8.</citation>
    <PMID>21284283</PMID>
  </reference>
  <reference>
    <citation>Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G; ADOPT Study Group; RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010 Sep;53(9):1838-45. doi: 10.1007/s00125-010-1804-y. Epub 2010 Jun 8.</citation>
    <PMID>20532476</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>May 7, 2015</lastchanged_date>
  <firstreceived_date>April 29, 2009</firstreceived_date>
  <firstreceived_results_date>October 6, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
